SLNO Valuation

Soleno Therapeutics Inc

Add to Watchlist

Advanced Chart

67.670

-0.74(-1.082%)1D

Overview
Forecast
Valuation
Earnings

SLNO Relative Valuation

SLNO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLNO is overvalued; if below, it's undervalued.

Historical Valuation

Soleno Therapeutics Inc (SLNO) is now in the Fair zone, suggesting that its current forward PS ratio of 13.09 is considered Fairly compared with the five-year average of -7.36. The fair price of Soleno Therapeutics Inc (SLNO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：67.67

Fair

52.18

Trailing

Forward

0.00

EV/EBITDA

Soleno Therapeutics Inc. (SLNO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

57.59

EV/EBIT

Soleno Therapeutics Inc. (SLNO) has a current EV/EBIT of 57.59. The 5-year average EV/EBIT is -4.40. The thresholds are as follows: Strongly Undervalued below -35.54, Undervalued between -35.54 and -19.97, Fairly Valued between 11.17 and -19.97, Overvalued between 11.17 and 26.75, and Strongly Overvalued above 26.75. The current Forward EV/EBIT of 57.59 falls within the Strongly Overvalued range.

13.09

Soleno Therapeutics Inc. (SLNO) has a current PS of 13.09. The 5-year average PS is 73.07. The thresholds are as follows: Strongly Undervalued below -386.82, Undervalued between -386.82 and -156.88, Fairly Valued between 303.01 and -156.88, Overvalued between 303.01 and 532.96, and Strongly Overvalued above 532.96. The current Forward PS of 13.09 falls within the Historic Trend Line -Fairly Valued range.

14.33

P/OCF

Soleno Therapeutics Inc. (SLNO) has a current P/OCF of 14.33. The 5-year average P/OCF is -7.35. The thresholds are as follows: Strongly Undervalued below -45.24, Undervalued between -45.24 and -26.29, Fairly Valued between 11.59 and -26.29, Overvalued between 11.59 and 30.53, and Strongly Overvalued above 30.53. The current Forward P/OCF of 14.33 falls within the Overvalued range.

31.64

P/FCF

Soleno Therapeutics Inc. (SLNO) has a current P/FCF of 31.64. The 5-year average P/FCF is 6.92. The thresholds are as follows: Strongly Undervalued below -104.85, Undervalued between -104.85 and -48.96, Fairly Valued between 62.80 and -48.96, Overvalued between 62.80 and 118.69, and Strongly Overvalued above 118.69. The current Forward P/FCF of 31.64 falls within the Historic Trend Line -Fairly Valued range.

Soleno Therapeutics Inc (SLNO) has a current Price-to-Book (P/B) ratio of 14.21. Compared to its 3-year average P/B ratio of 8.92 , the current P/B ratio is approximately 59.36% higher. Relative to its 5-year average P/B ratio of 6.25, the current P/B ratio is about 127.43% higher. Soleno Therapeutics Inc (SLNO) has a Forward Free Cash Flow (FCF) yield of approximately -2.35%. Compared to its 3-year average FCF yield of -44.98%, the current FCF yield is approximately -94.78% lower. Relative to its 5-year average FCF yield of -49.74% , the current FCF yield is about -95.28% lower.

14.21

P/B

Median3y

8.92

Median5y

6.25

-2.35

FCF Yield

Median3y

-44.98

Median5y

-49.74

Competitors Valuation Multiple

The average P/S ratio for SLNO's competitors is 9.75, providing a benchmark for relative valuation. Soleno Therapeutics Inc Corp (SLNO) exhibits a P/S ratio of 13.09, which is 34.28% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SLNO.O

Soleno Therapeutics Inc

MoonLake Immunotherapeutics

Loss

3.58B

PTGX.O

Protagonist Therapeutics Inc

Apellis Pharmaceuticals Inc

Mirum Pharmaceuticals Inc

6.74

64.09%

3.71B

Performance Decomposition

Market capitalization of SLNO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SLNO in the past 1 year is driven by Unknown.